We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva (TEVA) Q4 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.Last quarter, the company delivered in-line earnings.
This generic drug maker’s shares have lost 11.3% so far this year, while the Zacks classified Generic Drugs industry witnessed an increase of 2.1%.
Teva’s earnings have surpassed expectations in two of the last four quarters and met the same in the other two, delivering an average positive surprise of 2.59%.
Teva Pharmaceutical Industries Limited Price and EPS Surprise
Let’s see how things are shaping up for this announcement.
Factors to Consider
Teva’s generic segment could continue seeing weakness. The segment would remain under pressure due to pricing erosion as well as the absence of important product launches. Delays in product approvals and IP decisions as well as quality challenges experienced by third-party suppliers led to the lack of product launches in the third quarter. At the third quarter conference call, management had mentioned that these delays can hurt fourth-quarter sales, pushing some of the key generic product launches to the 2017–2018 timeframe.
Last quarter, U.S. legacy generics revenues declined due to lower sales of the generic versions of Pulmicort, Nexium and Xeloda, which resulted from loss of exclusivity and intense competition. We do not expect any improvement in the segment in the fourth quarter either.
In the fourth quarter, important launches included the generic versions of hypertension drugs Tribenzor, Azor and Beyaz (an oral contraceptive) in the U.S., which should provide some support to sales.
The EU generics segment will also remain under pressure with sales being affected by macro-economic conditions and healthcare reforms.
Meanwhile, in the branded segment, sales of both specialty products and blockbuster multiple sclerosis (MS) treatment Copaxone declined in the third quarter. It remains to be seen if sales pick up in the fourth quarter.
Investors will remain focused on Copaxone’s performance. We expect management to comment on the setback it suffered last week with the U.S. District Court for the District of Delaware invalidating all asserted claims of the ‘250, ‘413, ‘776 and ‘302 patents for Copaxone 40 mg.
Teva continues to focus on its cost reduction program which should give its profits a boost.
Earnings Whispers
Our proven model does not conclusively show that Teva is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP is 0.00% as both the Most Accurate estimate and the Zacks Consensus Estimate stand at $1.32. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Teva has a Zacks Rank #4. As it is, we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Some stocks in the healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are:
Acorda Therapeutics, Inc. is expected to release results on Feb 14. The company has an Earnings ESP of 5.56% and a Zacks Rank #3.
AMAG Pharmaceuticals, Inc. has an Earnings ESP of +3.23% and a Zacks Rank #3. The company is expected to release results on Feb 14.
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Teva (TEVA) Q4 Earnings: What's in Store for the Stock?
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.Last quarter, the company delivered in-line earnings.
This generic drug maker’s shares have lost 11.3% so far this year, while the Zacks classified Generic Drugs industry witnessed an increase of 2.1%.
Teva’s earnings have surpassed expectations in two of the last four quarters and met the same in the other two, delivering an average positive surprise of 2.59%.
Teva Pharmaceutical Industries Limited Price and EPS Surprise
Teva Pharmaceutical Industries Limited Price and EPS Surprise | Teva Pharmaceutical Industries Limited Quote
Let’s see how things are shaping up for this announcement.
Factors to Consider
Teva’s generic segment could continue seeing weakness. The segment would remain under pressure due to pricing erosion as well as the absence of important product launches. Delays in product approvals and IP decisions as well as quality challenges experienced by third-party suppliers led to the lack of product launches in the third quarter. At the third quarter conference call, management had mentioned that these delays can hurt fourth-quarter sales, pushing some of the key generic product launches to the 2017–2018 timeframe.
Last quarter, U.S. legacy generics revenues declined due to lower sales of the generic versions of Pulmicort, Nexium and Xeloda, which resulted from loss of exclusivity and intense competition. We do not expect any improvement in the segment in the fourth quarter either.
In the fourth quarter, important launches included the generic versions of hypertension drugs Tribenzor, Azor and Beyaz (an oral contraceptive) in the U.S., which should provide some support to sales.
The EU generics segment will also remain under pressure with sales being affected by macro-economic conditions and healthcare reforms.
Meanwhile, in the branded segment, sales of both specialty products and blockbuster multiple sclerosis (MS) treatment Copaxone declined in the third quarter. It remains to be seen if sales pick up in the fourth quarter.
Investors will remain focused on Copaxone’s performance. We expect management to comment on the setback it suffered last week with the U.S. District Court for the District of Delaware invalidating all asserted claims of the ‘250, ‘413, ‘776 and ‘302 patents for Copaxone 40 mg.
Teva continues to focus on its cost reduction program which should give its profits a boost.
Earnings Whispers
Our proven model does not conclusively show that Teva is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP is 0.00% as both the Most Accurate estimate and the Zacks Consensus Estimate stand at $1.32. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Teva has a Zacks Rank #4. As it is, we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Some stocks in the healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are:
BioMarin Pharmaceutical Inc. (BMRN - Free Report) is expected to release results on Feb 22. The company has an Earnings ESP of 7.50% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Acorda Therapeutics, Inc. is expected to release results on Feb 14. The company has an Earnings ESP of 5.56% and a Zacks Rank #3.
AMAG Pharmaceuticals, Inc. has an Earnings ESP of +3.23% and a Zacks Rank #3. The company is expected to release results on Feb 14.
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>